AI startup Lunit's 3D breast cancer screening tech hits U.S.

Korean medical startup Lunit’s AI-powered cancer diagnosis product Lunit Insight DBT is now commercially available in the United States after securing its first supply deal, two months after the U.S. Food and Drug Administration (FDA) approved it.

Lunit Insight DBT, Korean medical startup Lunit's latest AI-powered medical software that gained approval from the U.S. Food and Drug Administration [LUNIT]

Korean medical startup Lunit’s AI-powered cancer diagnosis product Lunit Insight DBT is now commercially available in the United States, two months after the U.S. Food and Drug Administration (FDA) approved it.

Lunit announced on Monday that it signed a supply deal with Tennessee-based medical company Mosaic Breast Imaging (MBI) for a year to provide two of its products, Lunit Insight DBT and Lunit Insight MMG.

Lunit Insight DBT is a software that can analyze 3D images generated by Digital Breast Tomosynthesis (DBT) equipment, an advanced imaging technology developed to improve the detection and diagnosis of breast abnormalities. DBT imaging offers a faster and more accurate breast cancer diagnosis compared to traditional 2D mammography screenings, according to the company.

Lunit Insight MMG is another AI-powered breast screening software that can detect breast abnormalities from 2D X-ray images. The product gained FDA approval in November 2021.

"The selection of Lunit's product by the highly trusted imaging center is significant, underscoring our commitment to advancing breast cancer diagnostics," Lunit CEO Suh Beom-seok said. "This supply agreement marks Lunit's initial foray into the U.S. market, and we are poised to channel our efforts into expanding our presence and strengthening our operations in the United States throughout the year.”

Last month, Lunit announced it would acquire New Zealand-based AI company Volpara Health Technologies for $193 million to propel its expansion in the U.S. market.

BY LEE JAE-LIM [lee.jaelim@joongang.co.kr]